Anlu Chen

Anlu Chen is a Senior Scientist I in Computational Oncology at AbbVie, where they lead bioinformatics analyses throughout the drug development pipeline and have pioneered novel drug target identification. Anlu completed a PhD in Genetics at Case Western Reserve University, where their research contributed to significant advancements in understanding rare Mendelian disorders and complex traits. Previously, as a Postdoctoral Fellow at the Broad Institute of MIT and Harvard, they focused on therapeutic targets for Type 2 Diabetes using advanced CRISPR techniques. Anlu's expertise encompasses CRISPR screening, data analysis, and molecular genetics, supported by several first-author publications in prestigious scientific journals.